↓ Skip to main content

MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients

Overview of attention for article published in BMC Genomic Data, February 2016
Altmetric Badge

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients
Published in
BMC Genomic Data, February 2016
DOI 10.1186/s12863-016-0348-7
Pubmed ID
Authors

Cielito C. Reyes-Gibby, Jian Wang, Mary Rose T. Silvas, Robert Yu, Sai-Ching J. Yeung, Sanjay Shete

Abstract

Genetic susceptibility plays an important role in the risk of developing pain in individuals with cancer. As a complex trait, multiple genes underlie this susceptibility. We used gene network analyses to identify novel target genes associated with pain in patients newly diagnosed with squamous cell carcinoma of the head and neck (HNSCC). We first identified 36 cancer pain-related genes (i.e., focus genes) from 36 publications based on a literature search. The Ingenuity Pathway Analysis (IPA) analysis identified additional genes that are functionally related to the 36 focus genes through pathway relationships yielding a total of 82 genes. Subsequently, 800 SNPs within the 82 IPA-selected genes on the Illumina HumanOmniExpress-12v1 platform were selected from a large-scale genotyping effort. Association analyses between the 800 candidate SNPs (covering 82 genes) and pain in a patient cohort of 1368 patients with HNSCC (206 patients with severe pain vs. 1162 with non-severe pain) showed the highest significance for MAPK1/ERK2, a gene belonging to the MAP kinase family (rs8136867, p value = 8.92 × 10(-4); odds ratio [OR] = 1.33, 95 % confidence interval [CI]: 1.13-1.58). Other top genes were PIK3C2G (a member of PI3K [complex], rs10770367, p value = 1.10 × 10(-3); OR = 1.46, 95 % CI: 1.16-1.82), TCRA (the alpha chain of T-cell receptor, rs6572493, p value = 2.84 × 10(-3); OR = 0.70, 95 % CI: 0.55-0.88), PDGFC (platelet-derived growth factor C, rs6845322, p value = 4.88 × 10(-3); OR = 1.32, 95 % CI: 1.09-1.60), and CD247 (a member of CD3, rs2995082, p value = 7.79 × 10(-3); OR = 0.76, 95 % CI: 0.62-0.93). Our findings provide novel candidate genes and biological pathways underlying pain in cancer patients. Further study of the variations of these candidate genes could inform clinical decision making when treating cancer pain.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 12%
Student > Doctoral Student 6 12%
Student > Bachelor 6 12%
Researcher 5 10%
Other 4 8%
Other 14 27%
Unknown 11 21%
Readers by discipline Count As %
Medicine and Dentistry 17 33%
Biochemistry, Genetics and Molecular Biology 5 10%
Nursing and Health Professions 3 6%
Neuroscience 3 6%
Agricultural and Biological Sciences 2 4%
Other 7 13%
Unknown 15 29%